JP Patent

JP6698643B2 — 多発性硬化症の治療のための組成物及び方法

Assigned to Cellix Bio Pvt Ltd · Expires 2020-05-27 · 6y expired

What this patent protects

Patent listed against remimazolam-besylate.

Drugs covered by this patent

Patent Metadata

Patent number
JP6698643B2
Jurisdiction
JP
Classification
—
Expires
2020-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Cellix Bio Pvt Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.